Kugan Sathiyanandarajah

Kugan Sathiyanandarajah (London) joined KKR in 2010 and is Head of KKR's Health Care Strategic Growth business in Europe. Mr. Sathiyanandarajah is a member of the Health Care industry team, and was based in KKR’s Menlo Park office from 2019 to 2020. He has played a significant role in a number of KKR’s investments across growth equity and private equity in both Europe and the U.S., including Gamma Biosciences, Argenta, Nordic Bioscience, Biosynth Carbosynth, Alliance Pharma, LGC Group, Walgreens Boots Alliance, Alvogen and Galenica. He currently serves on the board of directors of Gamma Biosciences, Argenta, Nordic Bioscience, Biosynth Carbosynth and EchoNous. Prior to joining KKR, he was with Goldman Sachs, where he was a member of the UK mergers and acquisitions team. Mr. Sathiyanandarajah earned an M.A. (First Class Hons) in Physical Natural Sciences (Chemistry) from the University of Cambridge.